A prototype blood-based screening test evaluated by Cleveland Clinic researchers and other experts can accurately identify the presence and originating site of 12 high-mortality cancer types, across all stages of progression, with a low false-positive rate, according to the latest results of an ongoing national clinical trial. Eric Klein, MD, Chairman of Cleveland Clinic’s Glickman Urological & Kidney Institute and the co-principal investigator of Cleveland Clinic’s portion of the study joins the Cancer Advances podcast to discuss this trial and the path forward to further validate this multi-cancer detection approach.